About GenTraceDx
To build a living cancer diagnostic that evolves with the science and with every patient’s journey.
Cancer does not stand still.
New treatments, biomarkers, and clinical trials emerge weekly, yet traditional genomic tests remain static, providing a one-time snapshot that quickly becomes outdated.
Our mission is simple but bold:
Create a diagnostic platform that keeps pace with the speed of cancer science.
GenTraceDx integrates high-fidelity multiomic profiling (tumour–normal WES + RNA) with autonomous, longitudinal reanalysis. Our system continuously re-interrogates each patient’s profile to identify new therapeutic pathways and clinical trial matches the moment new evidence emerges.
GenTraceDx replaces the static report with a continuously updating clinical intelligence system.
Built Through a Powerful Alliance Between Canada’s Leaders in Genomics and Diagnostics
GenTraceDx was formed through a strategic collaboration between global leaders in clinical diagnostics and cancer genomics.
Industry Lead
A 26-year leader in regulated diagnostics, Genetrack achieved Canada’s first FDA EUA and the country’s first Health Canada approval for a personalized vaccine trial. Through its specialized divisions, Genetrack is the exclusive designer and manufacturer of LDT clinical kits for leading global retail pharmacy chains, including CVS and Walgreens. With nationwide logistics and proprietary databases for over 3 million patients, Genetrack provides the proven manufacturing and regulatory engine for global-scale diagnostic deployment.
Research Lead
A world-renowned authority in cancer genomics, the GSC is a global pioneer in clinical-grade matched tumour-normal WES and RNA analysis at scale. The GSC developed GraphKB, the Nature-published architecture that unifies and standardizes fragmented global clinical evidence. With CAP, CLIA, and DAP accredited workflows that have sequenced thousands of patients, the GSC provides the elite scientific foundation for the platform.
Funding Partner
Genome BC connects researchers, industry, and government to accelerate the responsible use of genomics for societal and economic benefit.
Funding Partner
A leading genomics funding and innovation organization in Canada, supporting large-scale genomics research and translation initiatives across health, environment, and natural resources in British Columbia.
This partnership brings together world-class genomics, clinical infrastructure, and commercial execution to enable national deployment at scale.
Because static tests come too late, and miss too much.
- Are often limited to panels of selected genes
- Typically lack functional RNA insight
- May fail to detect rare or novel variants
- Provide a single static report
- Do not provide continuous updates as new evidence emerges
- Do not surface off-label DIN or SAP options
- Miss personalized vaccine insights
- Contribute to “no actionable findings” in 88% of patients
Patients deserve more.
Clinicians deserve more.
Cancer care deserves more.
GenTraceDx exists to deliver that “more.”
Multiomic. AI-Driven. Continuously Updating.
GenTraceDx integrates three core technologies into a single clinical workflow:
The result is a living diagnostic that evolves with each new breakthrough in cancer science.
No patient should miss a therapeutic opportunity because their test could not identify it.
- On-label targeted therapies
- Off-label DIN opportunities
- SAP-supported treatment options
- Real time clinical trial matching
- Combination therapy strategies
- Immunotherapy response biomarkers
- Personalized neoantigen vaccine design insights
We aim to empower oncologists with real-time, multiomic intelligence that, until now, has not existed in clinical practice.
A Platform Built for Patients
- Generating a proprietary, longitudinal dataset for global therapeutic insights
- Establishing the definitive data architecture for companion diagnostics and immunotherapy
- Providing clinical-grade diagnostic access to underserved and remote healthcare networks
- Generating multiomic real-world data for research and discovery
This pilot establishes the foundation for a new global standard in precision oncology.
Scaling a Global Platform
- MolDX reimbursement pathway
- Selective PMA/CDx submissions
- Collaborations with cancer agencies, hospitals, and academic centres
- Partnerships with pharma for CDx, RWE, and trial matching
- Continuous AI expansion for deeper evidence networks
GenTraceDx is positioned to become the global foundation for precision oncology.
Dr. June Wong
Vice President, Genetrack Biolabs
Dr. Steven Jones
